A Phase I/II Study of XELIRI Plus Bevacizumab as Second-Line Chemotherapy for Japanese Patients With Metastatic Colorectal Cancer (BIX Study)

BACKGROUND. Capecitabine is used mainly with oxaliplatin to treat metastatic colorectal cancer (mCRC). Results from capecitabine plus irinotecan (XELIRI) with or without bevacizumab (BV) have been reported in Europe but not in Japan. Consequently, the safety and efficacy of XELIRI plus BV in Japanes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Hamamoto, Yasuo, Yamaguchi, Tatsuro, Nishina, Tomohiro, Yamazaki, Kentaro, Ura, Takashi, Nakajima, Takako, Goto, Ayumu, Shimada, Ken, Nakayama, Norisuke, Sakamoto, Junichi, Morita, Satoshi, Yamada, Yasuhide
Format: Artigo
Sprache:Inglês
Veröffentlicht: AlphaMed Press 2014
Schlagworte:
Clinical Trial Results
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4221367/
https://ncbi.nlm.nih.gov/pubmed/25280489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0159
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge